EphA2 monoclonal antibodies and methods of making and using...

Details EphA2 monoclonal antibodies and methods of making and using... EphA2 monoclonal antibodies and methods of making and using...

2008-07-22

2008-07-22

Helms, Larry (Department: 1643)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Magnetic imaging agent

C530S388220, C435S007100

Reexamination Certificate

active

11004005

ABSTRACT:
The invention provides a monoclonal antibody, a fragment thereof, or a molecular complex thereof that binds to an extracellular domain of an EphA2 receptor molecule, wherein binding of the monoclonal antibody or fragment thereof to the EphA2 receptor molecule present in the membrane of a cancer cell favorably alters activity of the EphA2 receptor molecule. The invention further relates to methods of making and using the monoclonal antibodies, fragments, and molecular complexes regarding the same. The monoclonal antibodies of the present invention target the extracellular domain of EphA2 and operate to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells. The invention thus makes possible therapeutic strategies that optimally target metastatic cells while preventing collateral damage to normal tissues.

REFERENCES:
patent: 4472371 (1984-09-01), Burchiel et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5457048 (1995-10-01), Pasquale et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5585089 (1996-12-01), Queen et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5872223 (1999-02-01), Uckun
patent: 5876949 (1999-03-01), Dreyfuss et al.
patent: 5876950 (1999-03-01), Siadak et al.
patent: 5981245 (1999-11-01), Fox et al.
patent: 6057105 (2000-05-01), Hoon et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6174670 (2001-01-01), Wittwer et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6927203 (2005-08-01), Kinch et al.
patent: 7101976 (2006-09-01), Kilpatrick et al.
patent: 7192698 (2007-03-01), Kinch et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: 2001/0031262 (2001-10-01), Caplan et al.
patent: 2004/0028685 (2004-02-01), Kinch et al.
patent: 2004/0091486 (2004-05-01), Kinch et al.
patent: 2005/0152899 (2005-07-01), Kinch et al.
patent: 2006/0088541 (2006-04-01), Kinch et al.
patent: 2007/0086943 (2007-04-01), Kinch et al.
patent: 2007/0134254 (2007-06-01), Kinch et al.
patent: 2007/0161064 (2007-07-01), Kinch et al.
patent: 2007/0166314 (2007-07-01), Kinch et al.
patent: WO 93/00425 (1993-01-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/11020 (1994-05-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 95/15375 (1995-06-01), None
patent: WO 97/15587 (1997-05-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 00/37500 (2000-06-01), None
patent: WO 01/12172 (2001-02-01), None
patent: WO 01/12840 (2001-02-01), None
patent: WO 01/12840 (2001-02-01), None
patent: WO 01/47892 (2001-07-01), None
patent: WO 2003/094859 (2003-11-01), None
patent: WO 2003/094859 (2003-11-01), None
patent: WO 2003/099313 (2003-12-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 2005/051307 (2005-06-01), None
patent: WO 2005/051307 (2005-06-01), None
Ogawa et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization, Oncogene 2000, 19:6043-6052.
Cruse and Lewis. Illustrated Dictionary of Immunology. CRC Press. 1995. p. 241.
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Zantek ND et al. E-Cadherin Regulates the Function of the EphA2 receptor Tyrosine Kinase. Cell Growth & Differentiation. vol. 10, 629-638, Sep. 1999.
Walker-Daniels, “The Regulation of Elevated EphA2 Protein Levels in Metastatic Cancer Cells: Roles for Ligand Binding, Protein Degradation, and c-Cbl,” PhD. thesis, Purdue University, 119 pages (Cover Date Dec. 2001).
Zelinski, “Overexpression of the Receptor Tyrosine Kinase EphA2 Induces Malignant Transformation of Benign Mammary Epithelial: Implication for Increased Cell Survival and Altered Cellular Adhesions in Breast Cancer,” PhD. thesis, Purdue University, 131 pages (Cover Date Dec. 2001).
Scully et al., “Isolation and characterization of Dek, aDrosophilaeph receptor protein tyrosine kinase,” Mol Cell. Neuro., vol. 13(5), pp. 337-347 (1999).
“Immunochemistry,” LabFax, Kerr & Thorpe,ed., pp. 115, 157, 191-197 (1994).
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA, vol. 86, pp. 3833-3837 (May 1989).
Aasheim et al. “A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes.” 2000Blood.95(1):221-30.
Abrahmsen et al., “Engineering Sublilisin and Its Substrates for Efficient Ligation of Peptide Bonds in Aqueous Solution,” 1991Biochemistry, 30:4151-4159.
Agre et al. “The human tumor cloning assay in cancer drug development,” 1983Investigational New Drugs1:033-045.
Andres et al. “Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis.” 1994Oncogene9:1461-1467.
Angrist et al. “Chromosomal Localization of the Mouse Src-like Adapter Protein (Slap) Gene and Its putative Human Homolog SLA.” 1995Genomics30:623-625.
Bae et al. “Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.” 1993Breast Cancer Res. Treat.24:241-255.
Baggiolini et al. “Interleukin-8, a chemotactic and inflammatory cytokine.” 1992FEBS Lett., 307(1):97-101.
Baggliolini et al. “Interleukin-8 and the Chemokine Family.” 1995Int. J. Immunopharmae17(2):103-108.
Bartley et al. “B61 is a ligand for the ECK receptor protein-tyrosine kinase.” 1994Nature368:558-560.
Baselga et al. “Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
euOverexpressing Human Breast Cancer Xenografts.” 1998Cancer Res.58:2825-2831.
Becker et al. “Characterization of the SEK-1 receptor tyrosine kinase” 1995FEBS Letters368(2):353-357.
Behrens et al. “Cell-cell adhesion in invasion and metastasis of carcinomas.” 1994Cancer Treat. Res.71:251-266.
Biervert et al. “Semiquantitative expression analysis of ephrine-receptor tyrosine kinase mRNA's in a rat model of traumatic brain injury.” 2001Neurosci Lett.315(1-2):25-8.
Birchmeier “E-cadherin as a tumor (invasion) suppressor gene.” 1995Bioessays17:97-99.
Blanco et al. “Expression of EphA receptors and ligands during chick cerebellar development.” 2002 Mech. Dev. 114(1-2):225-9.
Bodanszky et al., Ed., Principles of Peptide Synthesis, Springer-Verlag Inc., NY, 1993, Cover pg., Publication pg., and Table of Contents.
Boerner et al.“Production of antigen-Specific Human Monoclonal Antibodies from in vitro-primed Human Splenocytes.” 1991J. Immunol.147(1):86-95.
Bohme et al. “PCR mediated detection of a new human receptor-tyrosine-kinase, HEK 2.” 1993Oncogene. 8(10):2857-62.
Bovenkamp et al. “Degenerate PCR-based cloning method for Eph receptors and analysis of their expression in the developing murine central nervous system and vasculature.” 2001DNA Cell Biol.20(4):203-13.
Bowie et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions.” 1990Science247:1306-1310.
Brady-Kalnay et al. “Dynamic Interaction of PTPμ with Multiple Cadherins In Vivo.” 1998J. Cell Biol.141:287-296.
Brantley et al. “Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.” 2002Oncogene.21(46):7011-26.
Brodeur et al. “Mouse-Human Myeloma Partners for the Production of Heterohybridomas, Monoclonal Antibody Production.” 1987Techniques and Application51-63.
Bruggemann et al. “Designer mice: the production of human antibody repertoires in transgenic animals.” 1993Year Immunol.7:33-40.
Burgess et al. “Po

Affiliated with

Also associated with

Rating

EphA2 monoclonal antibodies and methods of making and using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EphA2 monoclonal antibodies and methods of making and using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphA2 monoclonal antibodies and methods of making and using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3940947